New trials, publications, preprints and grants on this target, month by month.
Publication
Gramine Alleviates Ulcerative Colitis by Targeting COX-2 and Inhibiting Ferroptosis.
4 Nov 2026· Journal of ethnopharmacology· PUBMED
Publication
Protective effects of melatonin against bisphenol A-mediated endometrial tumorigenesis: An experimental study targeting COX-2-dependent MMP-9 expression.
1 Nov 2026· Taiwanese journal of obstetrics & gynecology· PUBMED
Publication
Integrated Transcriptomic and Network Pharmacology Identifies IRF1, PTGS2, TNF, and IFNG as Candidate Targets of Cortex Dictamni in Atopic Dermatitis.
23 Oct 2026· Journal of visualized experiments : JoVE· PUBMED
Publication
Overcoming primary non-response to infliximab in ulcerative colitis: monocyte-derived PTGS2 as a therapeutic target.
20 Oct 2026· Frontiers in immunology· PUBMED
Publication
Integrative network toxicology and pharmacology reveal that kaempferol alleviates BaP-triggered pulmonary fibrosis via suppressing Ras/COX-2-dependent cellular senescence.
15 Oct 2026· Frontiers in pharmacology· PUBMED
Publication
Novel acetophenonic-isoxazoline derivatives with potent anti-cancer and selective COX-2 inhibitory effects: Design, synthesis, and biological evaluation.
14 Oct 2026· Bioorganic chemistry· PUBMED
Publication
PTGS2/COX-2 is associated with neurovascular and blood-brain barrier changes in behaviourally classified MRL/lpr mice.
12 Oct 2026· Lupus science & medicine· PUBMED
Trial
Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer
1 Oct 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
More Than Pain Relief: COX-2 Inhibitors and the Disease-Modifying Promise of NSAIDs in Axial Spondyloarthritis.
1 Oct 2026· International journal of rheumatic diseases· PUBMED
Publication
Novel Pyrazole-4-Carbaldehyde Derivatives Having Potent COX-2 Inhibition and Anti-Tubercular Activity: Microwave-Assisted Green Synthesis and Molecular Docking.
1 Oct 2026· Journal of biochemical and molecular toxicology· PUBMED
Publication
Systems Toxicology Indicates AKT1/PTGS2-Centered Neuroinflammatory-Mitochondrial Crosstalk in Lidocaine Associated Neurotoxicity.
1 Oct 2026· CNS neuroscience & therapeutics· PUBMED
Publication
The deubiquitinating enzyme USP42 promotes lung adenocarcinoma progression through PTGS2.
26 Sept 2026· Journal of molecular histology· PUBMED
Publication
Integrative computational analysis of public fecal lipidomics and transcriptomics datasets suggests a candidate association between the COX-2 pathway and CE(20:4) in colorectal adenoma-carcinoma progression.
25 Sept 2026· PloS one· PUBMED
Publication
Integrated AUF-UPLC-MS and fraction-activity correlation to identify COX-2-targeted constituents of Shaoyao Gancao decoction.
21 Sept 2026· Frontiers in chemistry· PUBMED
Publication
Integrative Perspectives on COX-2 Signaling and Selective Inhibitors in Central Nervous System Disorders: A Narrative Review.
18 Sept 2026· Current medicinal chemistry· PUBMED
Publication
Therapeutic targeting of IL-17A-driven PTGS2/NLRP3 inflammasome activation in juvenile myelomonocytic leukemia.
17 Sept 2026· Blood· PUBMED
Publication
Quercetin Alleviates Ferroptosis-Induced Renal Fibrosis by Modulating the PRDM9/HMOX1/PTGS2 Axis.
16 Sept 2026· ACS omega· PUBMED
Publication
Inhibition of COX-2-Mediated Arachidonic Acid Metabolism by FGF21-PPARα Axis Alleviates Liver Steatosis.
15 Sept 2026· MedComm· PUBMED
Publication
6PPDQ exposure enhances susceptibility to ulcerative colitis by disturbing MMP9, PTGS2, and PPARG homeostasis: an integrative network toxicology and in vivo study.
12 Sept 2026· Chemico-biological interactions· PUBMED
Publication
Mitochondria-mediated anticancer effects of two previously characterized COX-2 inhibitors in hepatocellular carcinoma.
11 Sept 2026· Molecular and cellular biochemistry· PUBMED
Publication
H3K18la facilitates nasopharyngeal carcinoma progression through the activation of the IGF2BP1-COX2 signaling pathway.
8 Sept 2026· Frontiers in immunology· PUBMED
Publication
Anticancer Efficacy of HPPH-PDT Synergies with BCG-Immunotherapy or COX-2 Inhibitor in Treating Bladder Cancer.
7 Sept 2026· Molecular pharmaceutics· PUBMED
Publication
Development of Phenoxyacetic Acid Hybrids With COX-2 Inhibitory Activity as Potential Anti-Neuroinflammatory Agents.
1 Sept 2026· Drug development research· PUBMED
Publication
COX-2 Expression in Paired Primary Tumors and Lymph Node Metastases: An Exploratory Clinicopathological Study.
24 Aug 2026· Cancers· PUBMED
Publication
Imaging-guided COX-2 inhibition synergizes with photodynamic immunogenic cell death to potentiate checkpoint blockade in colon cancer.
18 Aug 2026· International journal of pharmaceutics: X· PUBMED
Publication
The CXCL5/CXCR2 Axis Attenuates Ferroptosis in Intrahepatic Cholangiocarcinoma Through the Positive Feedback Loop Between PTGS2 Transcriptional Activation and Neutrophil Recruitment.
17 Aug 2026· Advanced science (Weinheim, Baden-Wurttemberg, Germany)· PUBMED
Publication
Glycosylated Delphinidins, Natural Antioxidants, Functionally Modulate the COX-2/PGE2 Axis and Downregulate MDR1 in Glioblastoma Cells.
13 Aug 2026· Antioxidants (Basel, Switzerland)· PUBMED
Publication
MLN4924 suppresses pancreatic cancer progression and enhances chemosensitivity to gemcitabine by targeting the PTGS2/EGFR-PI3K/Akt/mTOR signaling axis.
11 Aug 2026· Anti-cancer drugs· PUBMED
Publication
BMSCs-AML cell interaction drives FLT3 inhibitor resistance through the NR2F2/COX-2/PGE2 Axis.
11 Aug 2026· Cellular signalling· PUBMED
Publication
Borneol exerts an enhanced anti-tumor effect on triple-negative breast cancer by targeting PTGS2 to reinforce gemcitabine-induced DNA damage.
3 Aug 2026· The Journal of pharmacy and pharmacology· PUBMED